[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-neovascularization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-neovascularization":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100642544","artificial-intelligence-assisted-lesion-based-urgent-referral-triage-of-ultra-widefield-retinal-images-100642544",false,"NCT07643129","Artificial Intelligence-Assisted Lesion-Based Urgent Referral Triage of Ultra-Widefield Retinal Images","Clinical Utility of an Artificial Intelligence-Assisted Lesion-Based Urgent Referral Triage System for Ultra-Widefield Retinal Images: A Prospective Multi-Reader Multi-Case Randomized Reader Study","ALERT-UWF","Inclusion Criteria:\n\n* Licensed ophthalmologists\n* Willing to participate as readers\n* Completion of study training\n\nExclusion Criteria:\n\n* Retinal specialists involved in establishing gold-standard labels\n* Prior access to gold-standard labels\n* Incomplete study participation",true,"ALL","18 Years",{"count":21,"type":22},8,"ESTIMATED","INTERVENTIONAL",[25],"NA","his study evaluates the clinical utility of an artificial intelligence (AI)-assisted lesion-based urgent referral triage system for ultra-widefield (UWF) retinal images.\n\nUnlike disease-classification systems, the AI system identifies predefined vision-threatening retinal findings and generates lesion-level urgent referral recommendations. Participating ophthalmologists will evaluate UWF retinal images under randomized AI-assisted and unassisted conditions.\n\nThe primary objective is to determine whether lesion-based AI assistance improves urgent referral triage performance compared with unaided image interpretation.",[28,29,30,31,32,33],"Vision-Threatening Retinal Lesions","Urgent Referral Retinal Findings","Retinal Detachment","Pre-retinal Hemorrhage","Subretinal Hemorrhage","Retinal Neovascularization",[35,36,37,38,39,40],"Artificial Intelligence","Urgent Referral","Lesion-Based Triage","Ultra-Widefield Imaging","Clinical Decision Support","Multi-Reader Multi-Case Study","NOT_YET_RECRUITING","2026-06-10",{"date":44,"type":45},"2026-06-15","ACTUAL",{"date":44,"type":22},{"date":48,"type":22},"2026-06-30",{"name":50,"class":51},"Xiamen Ophthalmology Center Affiliated to Xiamen University","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100561837","phase-2-efficacy-and-safety-of-intravitreal-injection-of-bevacizumab-with-and-without-oral-curcumin-100561837","NCT06595355","Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin","Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin in Diabetic Macular Edema","Inclusion Criteria:\n\nPatients with center-involving macular edema with macular center thickness more than 300 microns in OCT 2-Patients who did not receive intravitreal bevacizumab in the last 3 months and intravitreal corticosteroids in the last 6 months.\n\n3- The amount of BCVA should not be \\\u003C20\u002F400. 4-Consent to participate in the study\n\nExclusion Criteria:\n\n1. Other retinal diseases except for DME and macular edema due to other causes including uveitis, epiretinal membrane, central retinal vein occlusion, and...\n2. Existence of proliferative diabetic retinopathy and patients with a history of vitrectomy\n3. Patients with glaucoma, vitreous hemorrhage, age-related macular degeneration (ARMD)\n4. Media opacities that limit the interpretation of diagnostic tests\n5. Surgery or procedure 3 months before starting treatment\n6. Pregnancy or breastfeeding\n7. History of allergy to curcumin\n8. Use of warfarin\n9. Changing the patient's clinical diagnosis or the need for surgical interventions in the course of the disease\n10. Change in the patient's general health condition\n11. Absence of patient referrals\n12. Lack of consent to continue treatment and follow-up","40 Years",{"count":61,"type":22},52,[63,64],"PHASE2","PHASE3","The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema.\n\nA blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo).\n\nThe evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.",[67,68,33],"Diabetic Macular Edema","Macular Edema",[70,71,72,73,74,33],"macular edema","diabetic macular edema","central macular edema","bevacizumab","Diabetic Retinopathy","RECRUITING","2024-09-10",{"date":78,"type":45},"2024-09-19",{"date":80,"type":45},"2021-10-10",{"date":82,"type":22},"2025-09-22",{"name":84,"class":51},"Isfahan University of Medical Sciences",1]